Barclays’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $90.8K | Buy |
19,439
+16,625
| +591% | +$68.2K | ﹤0.01% | 4084 |
|
|
2026
Q1 | $11.6K | Sell |
2,814
-54,686
| -95% | -$205K | ﹤0.01% | 4675 |
|
|
2025
Q4 | $230K | Buy |
+57,500
| New | +$209K | ﹤0.01% | 4244 |
|
|
2025
Q2 | – | Sell |
-6,169
| Closed | -$43.8K | – | 5584 |
|
|
2025
Q1 | $43.8K | Sell |
6,169
-2,703
| -30% | -$37.2K | ﹤0.01% | 4649 |
|
|
2024
Q4 | $195K | Sell |
8,872
-384
| -4% | -$6.12K | ﹤0.01% | 4326 |
|
|
2024
Q3 | $186K | Buy |
9,256
+6,129
| +196% | +$128K | ﹤0.01% | 4339 |
|
|
2024
Q2 | $54.4K | Sell |
3,127
-11,830
| -79% | -$387K | ﹤0.01% | 4175 |
|
|
2024
Q1 | $624K | Sell |
14,957
-2,696
| -15% | -$75K | ﹤0.01% | 3457 |
|
|
2023
Q4 | $444K | Buy |
17,653
+4,915
| +39% | +$120K | ﹤0.01% | 3956 |
|
|
2023
Q3 | $417K | Buy |
12,738
+9,809
| +335% | +$428K | ﹤0.01% | 2912 |
|
|
2023
Q2 | $170K | Buy |
+2,929
| New | +$151K | ﹤0.01% | 3322 |
|
|
2022
Q3 | – | Sell |
-3
| Closed | – | – | 5178 |
|
|
2022
Q2 | $0 | Sell |
3
-257
| -99% | -$9.78K | ﹤0.01% | 5298 |
|
|
2022
Q1 | $14K | Hold |
260
| – | – | ﹤0.01% | 4537 |
|
|
2021
Q4 | $18K | Sell |
260
-70
| -21% | -$8.86K | ﹤0.01% | 3956 |
|
|
2021
Q3 | $52K | Sell |
330
-217
| -40% | -$35.7K | ﹤0.01% | 4100 |
|
|
2021
Q2 | $107K | Sell |
547
-161
| -23% | -$40.5K | ﹤0.01% | 3822 |
|
|
2021
Q1 | $183K | Buy |
708
+275
| +64% | +$72.3K | ﹤0.01% | 3743 |
|
|
2020
Q4 | $83K | Buy |
+433
| New | +$85.1K | ﹤0.01% | 4209 |
|
|
2020
Q3 | – | Sell |
-5
| Closed | -$1K | – | 5631 |
|
|
2020
Q2 | $1K | Buy |
+5
| New | +$1.37K | ﹤0.01% | 5476 |
|
|
2020
Q1 | – | Sell |
-585
| Closed | -$188K | – | 6504 |
|
|
2019
Q4 | $188K | Buy |
585
+390
| +200% | +$140K | ﹤0.01% | 5078 |
|
|
2019
Q3 | $74K | Buy |
+195
| New | +$77.2K | ﹤0.01% | 5701 |
|
|
2019
Q2 | – | Sell |
-8
| Closed | -$4K | – | 7327 |
|
|
2019
Q1 | $4K | Buy |
+8
| New | +$4.42K | ﹤0.01% | 6767 |
|
|
2018
Q4 | – | Sell |
-11
| Closed | -$3K | – | 7391 |
|
|
2018
Q3 | $3K | Buy |
11
+6
| +120% | +$2.54K | ﹤0.01% | 6913 |
|
|
2018
Q2 | $3K | Hold |
5
| – | – | ﹤0.01% | 6800 |
|
|
2018
Q1 | $22K | Buy |
+5
| New | +$14.5K | ﹤0.01% | 6397 |
|
Other funds holding XFOR
BCLSI
PA
SVCM
EAM
DTC
KCM
Barclays's XFOR Position: Q2 2026 in Review
Barclays increased its X4 Pharmaceuticals (XFOR) stake by 591% in Q2 2026, buying an estimated $68.2K and bringing the position to 19,439 shares worth $90.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4084.
Barclays first reported a position in XFOR in Q1 2018 and has held it in 25 quarters since. The position peaked at $624K in Q1 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.
- Barclays held 19,439 shares of X4 Pharmaceuticals worth $90.8K as of Q2 2026.
- Barclays bought 16,625 X4 Pharmaceuticals shares in Q2 2026, an estimated $68.2K.
- X4 Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4084 holding.
- Barclays first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 25 quarters since.
- Barclays's X4 Pharmaceuticals position peaked at $624K in Q1 2024.
- 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.